Overview
Molecular diagnostics and targeted cancer therapies are approaches that use the molecular and genetic features of tumors to detect, classify, and treat cancer with greater precision than conventional methods. Molecular diagnostics identify biomarkers, such as specific proteins, genes, or molecular alterations, that distinguish malignant from benign tissue or predict disease behavior, while targeted therapies act on the particular molecular pathways driving a given tumor. Together they enable earlier and more accurate diagnosis, prognosis, and treatment selection. This field is especially important for cancers where reliable markers are lacking and risk factors remain poorly understood, because a validated biomarker can guide clinical decisions and the development of new therapies. Key aspects include discovering candidate biomarkers, understanding the molecular mechanisms of tumor formation, and translating these findings into diagnostic tests and therapeutic targets. Related open-access research available here reports the identification of a novel biomarker for human uterine leiomyosarcoma, a malignancy that is difficult to distinguish from benign tumors, illustrating how molecular biomarker discovery supports improved diagnosis and the search for targeted treatments in cancers with unmet diagnostic needs.